For people with multiple sclerosis, an MS hug can be an unwelcome and painful part of their condition.
New research reveals how a dysfunction in the brain's so-called self-digestion system leads to cell death in neurodegenerative disorders. The newly discovered mechanism may lead to new therapies for conditions such as Parkinson's and Alzheimer's disease.
“We welcome this strong support from a group of experienced and successful investors who understand the need and market opportunity for new medicines to combat multi drug-resistant bacterial infections”
People with depression and social anxiety have some common and specific structural abnormalities in their brains that can be spotted in imaging scans.
Peptidream Inc. has scored another billion dollar-plus agreement to develop peptide-based therapies aimed at the treatment multiple disease targets.
Remarkable progress is being made on HIV treatment. Ahead of World AIDS Day, UNAIDS has launched a new report showing that access to treatment has risen significantly. In 2000, just 685 000 people living with HIV had access to antiretroviral therapy. By June 2017, around 20.9 million people had access to the life-saving medicines. Such a dramatic scale-up could not have happened without the courage and determination of people living with HIV demanding and claiming their rights, backed up by steady, strong leadership and financial commitment.
It is estimated by The National Kidney Foundation that over 100,000 patients are on the waiting list for kidney donors. A further 3,000 names are added to the list every year. An average patient has to wait for 3.6 years for a viable transplant. The patients are treated with dialysis while they are waiting for a transplant and only one in three patients survive for more than five years without a transplant. All that could change as scientists have developed the world’s first artificial kidney.
Celgene Corporation and bluebird bio, Inc. announced that bb2121, a chimeric antigen receptor T-cell (CAR-T) therapy targeting b-cell maturation antigen (BCMA) in previously treated patients with multiple myeloma, has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) and PRIority MEdicines (PRIME) eligibility by the European Medicines Agency (EMA).
Keele University researchers have designed a new dye that can be used to observe the electrical activity of neurons in the brain and could lead to finding a new and more efficient way of treating neurological diseases, as presented at the Society for Neuroscience annual conference in Washington, D.C. this week.
Perflow Medical, an Israeli-based medtech company focused on next-generation neurointerventional devices,announced the issuance of U.S. Patent No. 9510855, by the U.S. Patent and Trademark Office (USPTO), for the Stream™ Dynamic Neuro-Thrombectomy Net. This is the first device to provide full dynamic wall apposition during the treatment of acute ischemic stroke.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.